Press release content from Business Wire. The AP news staff was not involved in its creation.
Revance Provides Corporate Update and Anticipated Milestones for 2021
January 7, 2021 GMT
NASHVILLE, Tenn. (BUSINESS WIRE) Jan 7, 2021
Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today provided a corporate update, product pipeline timing and anticipated milestones for 2021.
Financial Update and Key Launch Metrics:
Preliminary Unaudited Full Year 2020 RHA® Collection Revenue of Between $12.5 Million and $13.0 Million. The company expects its first full quarter of unaudited RHA® Collection revenue to be between $9.5 million and $10.0 million for the fourth quarter 2020, bringing full year RHA® Collection revenue to be between $12.5 million and $13.0 million. The company launched the RHA® Collection in September 2020.
ALDX Catches Eye, RVNC Faces Busy Year Ahead, SRPT Plunges On DMD Trial Data
BEIJING (dpa-AFX) - Today s Daily Dose brings you news about Alnylam s transthyretin-mediated (ATTR) amyloidosis trial results; Sarepta s mixed results of investigational gene therapy SRP-9001 in patients with Duchenne muscular dystrophy; Aldeyra s dry eye disease trial results; and Revance s anticipated milestones.
Read on.
1. Aldeyra Catches Investor s Eye
Aldeyra Therapeutics Inc. s (ALDX) run-in cohort of phase III trial of Reproxalap in patients with dry eye disease has achieved statistical significance for ocular redness, an FDA-approvable sign, and clinical symptoms of ocular dryness and discomfort.
Dry eye disease is a common inflammatory disease affecting an estimated 34 million or more adults in the United States. The disease is characterized by insufficient moisture and lubrication in the anterior surface of the eye, leading to dryness, inflammation, pain, discomfort, irritation, diminished q